WO2004018002A3 - Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells - Google Patents

Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells Download PDF

Info

Publication number
WO2004018002A3
WO2004018002A3 PCT/EP2003/009341 EP0309341W WO2004018002A3 WO 2004018002 A3 WO2004018002 A3 WO 2004018002A3 EP 0309341 W EP0309341 W EP 0309341W WO 2004018002 A3 WO2004018002 A3 WO 2004018002A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsp70
granzyme
tumor cells
apoptosis
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009341
Other languages
French (fr)
Other versions
WO2004018002A2 (en
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DK03792414.9T priority Critical patent/DK1537204T3/en
Priority to AT03792414T priority patent/ATE457349T1/en
Priority to JP2004530248A priority patent/JP4699755B2/en
Priority to DE60331228T priority patent/DE60331228D1/en
Priority to EP03792414A priority patent/EP1537204B1/en
Priority to CA002535952A priority patent/CA2535952A1/en
Priority to SI200331798T priority patent/SI1537204T1/en
Priority to AU2003260452A priority patent/AU2003260452A1/en
Priority to US10/526,586 priority patent/US7722863B2/en
Publication of WO2004018002A2 publication Critical patent/WO2004018002A2/en
Publication of WO2004018002A3 publication Critical patent/WO2004018002A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07—Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to a method of inducing or enhancing the expression of granzyme B in natural killer (NK) cells. The present invention relates also to a use of said NK cells for the preparation of a pharmaceutical composition for the treatment of tumors, viral or bacterial infections or inflammatory diseases. Further, the present invention relates to the use of granzyme B for the treatment of tumors, viral or bacterial infections or inflammatory diseases, wherein the tumor cells or the cells affected by said infection or inflammation express Hsp70 in their cell surface.
PCT/EP2003/009341 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells Ceased WO2004018002A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK03792414.9T DK1537204T3 (en) 2002-08-23 2003-08-22 Granzym B as HSP70 / HSP70 peptide-dependent triggers of programmed cell death in tumor cells
AT03792414T ATE457349T1 (en) 2002-08-23 2003-08-22 GRANZYME B AS AN HSP70/HSP70 PEPTIDE-DEPENDENT APOPTOSIS TRIGGER IN TUMOR CELLS
JP2004530248A JP4699755B2 (en) 2002-08-23 2003-08-22 Use of granzyme B as an Hsp70 / Hsp70 peptide-dependent inducer of apoptosis in tumor cells
DE60331228T DE60331228D1 (en) 2002-08-23 2003-08-22 GRANZYME B AS A HSP70 / HSP70 PEPTIDE-DEPENDANT APOPTOSAUSES IN TUMOR CELLS
EP03792414A EP1537204B1 (en) 2002-08-23 2003-08-22 Granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
CA002535952A CA2535952A1 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
SI200331798T SI1537204T1 (en) 2002-08-23 2003-08-22 Granzim b as the pathogen of apoptosis is dependent on Hsp Hsp peptide in tumor cells
AU2003260452A AU2003260452A1 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
US10/526,586 US7722863B2 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018284.6 2002-08-23
EP02018284 2002-08-23

Publications (2)

Publication Number Publication Date
WO2004018002A2 WO2004018002A2 (en) 2004-03-04
WO2004018002A3 true WO2004018002A3 (en) 2004-06-17

Family

ID=31896833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009341 Ceased WO2004018002A2 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells

Country Status (13)

Country Link
US (1) US7722863B2 (en)
EP (1) EP1537204B1 (en)
JP (1) JP4699755B2 (en)
AT (1) ATE457349T1 (en)
AU (1) AU2003260452A1 (en)
CA (1) CA2535952A1 (en)
CY (1) CY1110005T1 (en)
DE (1) DE60331228D1 (en)
DK (1) DK1537204T3 (en)
ES (1) ES2340270T3 (en)
PT (1) PT1537204E (en)
SI (1) SI1537204T1 (en)
WO (1) WO2004018002A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2395294C2 (en) * 2004-06-18 2010-07-27 Дженентек, Инк. Methods of applying of apo-2l-receptors agonists and nk-cells activators

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079833A1 (en) * 2006-11-14 2009-07-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Compositions and methods for immunotherapy
KR101192724B1 (en) 2010-02-04 2012-10-18 한국생명공학연구원 Activation method for Natural killer cell via regulating microRNA expression
WO2012024666A2 (en) 2010-08-20 2012-02-23 Immunovative Therapies, Ltd. Cells expressing th1 characteristics and cytolytic properties
WO2018005926A1 (en) 2016-07-01 2018-01-04 The General Hospital Corporation Granzyme b directed imaging and therapy
US12053505B2 (en) 2017-08-31 2024-08-06 Multimmune Gmbh Hsp70 based combination therapy
CN115477705B (en) * 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of a chimeric antigen receptor immune cell constructed based on granzyme B
CN115305238B (en) * 2022-09-19 2023-11-17 杭州凤喆凰生物科技有限公司 Application of component for improving natural killer cell killing power in natural killer cell culture

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009206A1 (en) * 1997-08-18 1999-02-25 Center For Blood Research, Inc. Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis
WO1999043840A1 (en) * 1998-02-27 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
WO1999049881A2 (en) * 1998-03-27 1999-10-07 Gabriele Multhoff Application of hsp70 proteins
FR2792205A1 (en) * 1999-04-19 2000-10-20 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITION COMPRISING NKT CELLS ACTIVATED BY IMP, AND ITS USE IN THERAPY
US6261839B1 (en) * 1998-03-27 2001-07-17 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Method for the induction of a NK cell-mediated immune response
WO2001080880A2 (en) * 2000-04-22 2001-11-01 Stefan Barth Apoptotic agents
WO2002022656A2 (en) * 2000-09-13 2002-03-21 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009206A1 (en) * 1997-08-18 1999-02-25 Center For Blood Research, Inc. Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis
WO1999043840A1 (en) * 1998-02-27 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
WO1999049881A2 (en) * 1998-03-27 1999-10-07 Gabriele Multhoff Application of hsp70 proteins
US6261839B1 (en) * 1998-03-27 2001-07-17 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Method for the induction of a NK cell-mediated immune response
FR2792205A1 (en) * 1999-04-19 2000-10-20 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITION COMPRISING NKT CELLS ACTIVATED BY IMP, AND ITS USE IN THERAPY
WO2001080880A2 (en) * 2000-04-22 2001-11-01 Stefan Barth Apoptotic agents
WO2002022656A2 (en) * 2000-09-13 2002-03-21 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CELL STRESS AND CHAPERONES, vol. 6, no. 4, October 2001 (2001-10-01), pages 337 - 344, ISSN: 1355-8145 *
CELL STRESS AND CHAPERONES, vol. 7, no. 4, - October 2002 (2002-10-01), pages 365 - 373 *
CELLULAR IMMUNOLOGY, vol. 180, no. 1, 1997, pages 1 - 9, ISSN: 0008-8749 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 17 October 2003 (2003-10-17), GROSS CATHARINA ET AL: "Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B.", XP002276406, Database accession no. PREV200300583456 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, HOMMEL-BERREY GRACE A ET AL: "Granzyme B independently of perforin mediates noncytolytic intracellular inactivation of vesicular stomatitis virus", XP002276404, Database accession no. PREV199799800859 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2001 (2001-10-01), MULTHOFF GABRIELE ET AL: "A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity", XP002276403, Database accession no. PREV200200042332 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MOSER ET AL: "INHIBITION OF TUMOR GROWTH IN MICE WITH SEVERE COMBINED IMMUNODEFICIENCY IS MEDIATED BY HEAT SHOCK PROTEIN 70 (HSP70) - PEPTIDE - ACTIVATED, CD94 POSITIVE NATURAL KILLER CELLS", XP002276405, Database accession no. NLM12653481 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 42, 17 October 2003 (2003-10-17), pages 41173 - 41181, ISSN: 0021-9258 *
SHAFER W M ET AL: "HUMAN LYSOSOMAL CATHEPSIN G AND GRANZYME B SHARE A FUNCTIONALLY CONSERVED BROAD SPECTRUM ANTIBACTERIAL PEPTIDE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 1, 1991, pages 112 - 116, XP002276402, ISSN: 0021-9258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2395294C2 (en) * 2004-06-18 2010-07-27 Дженентек, Инк. Methods of applying of apo-2l-receptors agonists and nk-cells activators

Also Published As

Publication number Publication date
ATE457349T1 (en) 2010-02-15
EP1537204B1 (en) 2010-02-10
CY1110005T1 (en) 2015-01-14
JP4699755B2 (en) 2011-06-15
EP1537204A2 (en) 2005-06-08
AU2003260452A8 (en) 2004-03-11
PT1537204E (en) 2010-05-05
ES2340270T3 (en) 2010-06-01
US20060111285A1 (en) 2006-05-25
WO2004018002A2 (en) 2004-03-04
DK1537204T3 (en) 2010-06-07
JP2006507810A (en) 2006-03-09
SI1537204T1 (en) 2010-06-30
DE60331228D1 (en) 2010-03-25
AU2003260452A1 (en) 2004-03-11
CA2535952A1 (en) 2004-03-04
US7722863B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
DE69929232D1 (en) VIRUSELY PARTICLES FOR INDUCING AUTOANTIC BODIES
MY140539A (en) 1-amino 1h-imidazoquinolines
AU2002305450A1 (en) Proteomimetic compounds and methods
BRPI0418251B8 (en) phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2005030121A3 (en) Compounds, compositions and methods
MX2007001638A (en) Binding domain fusion proteins.
BRPI0510475B8 (en) recombinant chimeric adenovirus, its use in the treatment of cancer and methods of inhibiting the growth of a cancer cell, providing a therapeutic protein to a cell, and isolating the adenovirus
BRPI0416936A (en) substituted imidazo ring systems and methods
EA200700886A1 (en) CONNECTION OF TIADIAZOLE AND ITS APPLICATION
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
AU2003263552A1 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
EA200600424A1 (en) APPLICATION OF POLYPEPTIDES OF THE FAMILY OF KUPREDOXINS IN TREATMENT OF CANCER
ATE374251T1 (en) COMPOSITIONS FOR GENE THERAPY OF DIABETES
CY1110005T1 (en) GRANZYM B AS A DISTRIBUTOR OF CELL TUMORS DEPENDENT ON A HSP70 / HSP70 Peptide
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
BR0009170A (en) akt nucleic acids, polypeptides and their use
GB0418388D0 (en) Cell therapy
WO2004087766A3 (en) Peptabody for cancer treatment
WO2021212010A3 (en) Small molecule antiviral drug treatment for human papillomavirus infections
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004530248

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003792414

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003792414

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006111285

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10526586

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2535952

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 10526586

Country of ref document: US